BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25255207)

  • 1. Fortification of blood plasma from cancer patients with human serum albumin decreases the concentration of cisplatin-derived toxic hydrolysis products in vitro.
    Morris TT; Ruan Y; Lewis VA; Narendran A; Gailer J
    Metallomics; 2014 Nov; 6(11):2034-41. PubMed ID: 25255207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.
    Sooriyaarachchi M; Narendran A; Gailer J
    Metallomics; 2011 Jan; 3(1):49-55. PubMed ID: 21135941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of sodium thiosulfate on the metabolism of cis-platin in human plasma in vitro.
    Sooriyaarachchi M; Narendran A; Gailer J
    Metallomics; 2012 Aug; 4(9):960-7. PubMed ID: 22842879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetyl-L-cysteine modulates the metabolism of cis-platin in human plasma in vitro.
    Sooriyaarachchi M; Narendran A; Gailer J
    Metallomics; 2013 Mar; 5(3):197-207. PubMed ID: 23443244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprotection by D-methionine against cisplatin-induced side-effects: insight from in vitro studies using human plasma.
    Sooriyaarachchi M; White WM; Narendran A; Gailer J
    Metallomics; 2014 Mar; 6(3):532-41. PubMed ID: 24337005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The study of possibility to elevate antitumor activity and decrease of systemic toxic effects of cisplatin by its binding with deliganded albumin.
    Sakhno LA; Sarnatskaya VV; Yushko LA; Melnikov OR; Momot VY; Korneeva LN; Svintsiskiy VS; Korotich VG; Nechitaylo II; Nikolaev VG
    Exp Oncol; 2006 Dec; 28(4):303-7. PubMed ID: 17285115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction of platinum-based drugs with native biologically relevant proteins.
    Brauckmann C; Wehe CA; Kieshauer M; Lanvers-Kaminsky C; Sperling M; Karst U
    Anal Bioanal Chem; 2013 Feb; 405(6):1855-64. PubMed ID: 23052861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability, accumulation and cytotoxicity of an albumin-cisplatin adduct.
    Møller C; Tastesen HS; Gammelgaard B; Lambert IH; Stürup S
    Metallomics; 2010 Dec; 2(12):811-8. PubMed ID: 21085722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection.
    Martinčič A; Cemazar M; Sersa G; Kovač V; Milačič R; Ščančar J
    Talanta; 2013 Nov; 116():141-8. PubMed ID: 24148385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the safety of metal-based drugs by tuning their metabolism with chemoprotective agents.
    Gailer J
    J Inorg Biochem; 2018 Feb; 179():154-157. PubMed ID: 29137811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.
    Bell DN; Liu JJ; Tingle MD; Rattel B; Meyer TU; McKeage MJ
    Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1440-6. PubMed ID: 18671714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
    Viale M; Vannozzi MO; Pastrone I; Mariggiò MA; Zicca A; Cadoni A; Cafaggi S; Tolino G; Lunardi G; Civalleri D; Lindup WE; Esposito M
    J Pharmacol Exp Ther; 2000 Jun; 293(3):829-36. PubMed ID: 10869382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gel electrophoresis in combination with laser ablation-inductively coupled plasma mass spectrometry to quantify the interaction of cisplatin with human serum albumin.
    Sullivan MP; Morrow SJ; Goldstone DC; Hartinger CG
    Electrophoresis; 2019 Sep; 40(18-19):2329-2335. PubMed ID: 31087392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy.
    Khalaila I; Bergamo A; Bussy F; Sava G; Dyson PJ
    Int J Oncol; 2006 Jul; 29(1):261-8. PubMed ID: 16773208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin.
    Timerbaev AR; Aleksenko SS; Polec-Pawlak K; Ruzik R; Semenova O; Hartinger CG; Oszwaldowski S; Galanski M; Jarosz M; Keppler BK
    Electrophoresis; 2004 Jul; 25(13):1988-1995. PubMed ID: 15237398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noncovalent interactions between a trinuclear monofunctional platinum complex and human serum albumin.
    Wang Y; Wang X; Wang J; Zhao Y; He W; Guo Z
    Inorg Chem; 2011 Dec; 50(24):12661-8. PubMed ID: 22077361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
    Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
    Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.